Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine.
Sign Up to like & getrecommendations! Published in 2019 at "Blood reviews"
DOI: 10.1016/j.blre.2019.100618
Abstract: Patients with haemophilia A (HA) or B (HB) experience spontaneous limb- or life-threatening bleedings which are prevented by regular prophylactic intravenous infusions of the deficient coagulation factor (FVIII or FIX). Prophylaxis with subcutaneous long-acting non-factor… read more here.
Keywords: medicine; haemophilia; treatment; factor products ... See more keywords
How Does The Scottish Medicines Consortium Assess The Value Of Orphan And Ultra-Orphan Drugs?
Sign Up to like & getrecommendations! Published in 2017 at "Value in Health"
DOI: 10.1016/j.jval.2017.08.964
Abstract: Objectives: In Germany the reimbursement of inpatient factor products is negotiated between hospitals and statutory sick funds on region or on hospitals level. The payment for groups of factors or each individual product brand is… read more here.
Keywords: established products; scottish medicines; factor products; value ... See more keywords
Current and future therapies for haemophilia—Beyond factor replacement therapies
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18379
Abstract: Some non‐factor products that work by facilitating the coagulation pathway (emicizumab) and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for patients with haemophilia (H) have been developed, and clinical trials using these products are… read more here.
Keywords: factor products; factor; non factor; future therapies ... See more keywords